Cardiovalve Reaches 2 Milestones for its Tricuspid Valve Replacement System
Cardiovalve has a pair of milestones that could help catapult the company into the forefront of the tricuspid valve market. The Or Yehuda, Israel-based company received FDA approval for an early feasibility study of the transcatheter tricuspid valve replacement system and Breakthrough Device Designation for the technology.
The studyâs primary endpoint is the safety and feasibility of the Cardiovalve technology and procedure in reducing tricuspid regurgitation, with evaluations at 30 days and periodically up to five years. The study will be conducted in collaboration with five leading US hospitals.
In a release Cardiovalveâs CEO Amir Gross, CEO said, "We are excited about the FDAâs recognition of the potential clinical benefit of the Transcatheter Tricuspid Valve Replacement System. We now have clinical data two years out that our implant is functioning as expected and the patient is improved clinically. FDAâs âbreakthroughâ designation validates and reaffirms our commitment to improving and extending the lives of millions of patients suffering from heart valve disease across the world."
Cardiovalve isnât the only company that has made significant strides in the tricuspid valve space. In September of last year, Abbott Laboratories had a significant milestone in space by nabbing an IDE for the TriClip from FDA. Abbott's IDE study is set to enroll 700 pat...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Cardiovascular Source Type: news
More News: Canada Health | Cardiology | Cardiovascular | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Hospitals | Israel Health | Medical Devices | Mergers and Aquisitions | Middle East Health | Study